DekaBank Deutsche Girozentrale Acquires Shares of 38,200 Sangamo Therapeutics Inc (SGMO)

DekaBank Deutsche Girozentrale acquired a new position in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 38,200 shares of the biopharmaceutical company’s stock, valued at approximately $753,000.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. raised its position in shares of Sangamo Therapeutics by 29.3% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 18,962 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 4,300 shares during the last quarter. Swiss National Bank raised its position in shares of Sangamo Therapeutics by 3.9% during the fourth quarter. Swiss National Bank now owns 142,460 shares of the biopharmaceutical company’s stock worth $2,336,000 after acquiring an additional 5,400 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Sangamo Therapeutics by 70.0% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 19,189 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 7,900 shares during the last quarter. Fred Alger Management Inc. bought a new position in shares of Sangamo Therapeutics during the fourth quarter worth about $148,000. Finally, Xact Kapitalforvaltning AB bought a new position in shares of Sangamo Therapeutics during the fourth quarter worth about $175,000. Institutional investors own 63.74% of the company’s stock.

In related news, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $15.38, for a total transaction of $76,900.00. Following the completion of the sale, the chief financial officer now owns 12,250 shares of the company’s stock, valued at $188,405. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Curt A. Herberts III sold 2,278 shares of the firm’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $18.30, for a total value of $41,687.40. The disclosure for this sale can be found here. Insiders have sold 81,539 shares of company stock valued at $1,734,825 in the last ninety days. 1.20% of the stock is currently owned by insiders.

A number of equities analysts have recently issued reports on SGMO shares. BidaskClub downgraded Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 17th. Zacks Investment Research downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 10th. Wedbush restated a “neutral” rating and set a $6.00 price objective on shares of Sangamo Therapeutics in a research report on Monday, February 12th. Barclays restated a “buy” rating and set a $30.00 price objective on shares of Sangamo Therapeutics in a research report on Sunday, February 25th. Finally, Jefferies Group restated a “buy” rating on shares of Sangamo Therapeutics in a research report on Friday, February 23rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. Sangamo Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $21.67.

Sangamo Therapeutics opened at $15.95 on Monday, according to MarketBeat Ratings. Sangamo Therapeutics Inc has a one year low of $6.55 and a one year high of $27.50. The company has a market cap of $1.62 billion, a P/E ratio of -22.79 and a beta of 2.83. The company has a quick ratio of 4.78, a current ratio of 4.78 and a debt-to-equity ratio of 0.14.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the consensus estimate of $0.29 by ($0.52). Sangamo Therapeutics had a negative return on equity of 30.96% and a negative net margin of 126.96%. The business had revenue of $12.60 million for the quarter, compared to analyst estimates of $53.09 million. During the same period in the prior year, the business earned ($0.23) EPS. The company’s revenue for the quarter was up 270.6% on a year-over-year basis. research analysts predict that Sangamo Therapeutics Inc will post -0.54 EPS for the current fiscal year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply